162 related articles for article (PubMed ID: 36176911)
1. Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer.
Zheng C; Zhang W; Wang J; Zhai Y; Xiong F; Cai Y; Gong X; Zhu B; Zhu HH; Wang H; Li Y; Zhang P
Acta Pharm Sin B; 2022 Sep; 12(9):3726-3738. PubMed ID: 36176911
[TBL] [Abstract][Full Text] [Related]
2. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
[TBL] [Abstract][Full Text] [Related]
3. Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy.
Wang Z; Cordova LE; Chalasani P; Lu J
Mol Pharm; 2022 Dec; 19(12):4665-4674. PubMed ID: 36413426
[TBL] [Abstract][Full Text] [Related]
4. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
5. Adenosine-modulating synthetic high-density lipoprotein for chemoimmunotherapy of triple-negative breast cancer.
Gong X; Zheng C; Cai Y; Zhang W; Zhu B; Rong R; Kong Y; Zhang Y; Wang J; Li Y; Zhang P
J Control Release; 2024 Mar; 367():637-648. PubMed ID: 38295994
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma Growth Retardation and PD-1 Blockade Therapy Potentiation with Synthetic High-density Lipoprotein.
Wang J; Meng J; Ran W; Lee RJ; Teng L; Zhang P; Li Y
Nano Lett; 2019 Aug; 19(8):5266-5276. PubMed ID: 31361965
[TBL] [Abstract][Full Text] [Related]
7. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
8. Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer.
Wang T; Subramanian C; Yu M; White PT; Kuai R; Sanchez J; Moon JJ; Timmermann BN; Schwendeman A; Cohen MS
Surgery; 2019 Dec; 166(6):1168-1175. PubMed ID: 31371177
[TBL] [Abstract][Full Text] [Related]
9. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
10. Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma.
Deng H; Kan A; Lyu N; Mu L; Han Y; Liu L; Zhang Y; Duan Y; Liao S; Li S; Xie Q; Gao T; Li Y; Zhang Z; Zhao M
Liver Cancer; 2020 Jun; 9(3):338-357. PubMed ID: 32647635
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine-loaded synthetic high-density lipoprotein preferentially eradicates hepatic monocyte-derived macrophages in mouse liver with colorectal cancer metastases.
Xiong FQ; Zhang W; Zheng C; Li Y; Gong X; Zhang Y; Wang H; Zhang PC; Li YP
Acta Pharmacol Sin; 2023 Nov; 44(11):2331-2341. PubMed ID: 37225846
[TBL] [Abstract][Full Text] [Related]
12. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
[TBL] [Abstract][Full Text] [Related]
13. Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer.
Liu Y; Qiu N; Shen L; Liu Q; Zhang J; Cheng YY; Lee KH; Huang L
J Control Release; 2020 Jul; 323():431-441. PubMed ID: 32360890
[TBL] [Abstract][Full Text] [Related]
14. Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies.
Nahar S; Huang Y; Nagy BA; Zebala JA; Maeda DY; Rudloff U; Oppenheim JJ; Yang D
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190294
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer.
Lee JS; Yost SE; Yuan Y
Front Oncol; 2020; 10():582185. PubMed ID: 33505906
[TBL] [Abstract][Full Text] [Related]
16. Abscopal Effect of Radiotherapy Enhanced with Immune Checkpoint Inhibitors of Triple Negative Breast Cancer in 4T1 Mammary Carcinoma Model.
Song HN; Jin H; Kim JH; Ha IB; Kang KM; Choi HS; Jeong HJ; Kim MY; Kim HJ; Jeong BK
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638817
[TBL] [Abstract][Full Text] [Related]
17. Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.
Pilones KA; Hensler M; Daviaud C; Kraynak J; Fucikova J; Galluzzi L; Demaria S; Formenti SC
Oncoimmunology; 2020 Oct; 9(1):1830524. PubMed ID: 33150045
[TBL] [Abstract][Full Text] [Related]
18. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Gao M; Wang T; Ji L; Bai S; Tian L; Song H
Front Immunol; 2020; 11():366. PubMed ID: 32194569
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer.
Zanker DJ; Spurling AJ; Brockwell NK; Owen KL; Zakhour JM; Robinson T; Duivenvoorden HM; Hertzog PJ; Mullins SR; Wilkinson RW; Parker BS
Clin Transl Immunology; 2020; 9(9):e1177. PubMed ID: 33005415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
